Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis by Garassino, Marina Chiara et al.
  1Garassino MC, et al. ESMO Open 2018;3:e000327. doi:10.1136/esmoopen-2018-000327
Open access 
Chemotherapy versus erlotinib as 
second-line treatment in patients with 
advanced non-small cell lung cancer and 
wild-type epidermal growth factor 
receptor: an individual patient data 
(IPD) analysis
Marina Chiara Garassino,1 Tomoya Kawaguchi,2 Vanesa Gregorc,3 Eliana Rulli,4 
Masahiko Ando,5 Silvia Marsoni,6 Shun-ichi Isa,7 Silvia Novello,8 Gabriella Farina,9 
Sandro Barni,10 Valter Torri,4 Michela Cinquini4 
Review
To cite: Garassino MC, 
Kawaguchi T, Gregorc V, et al. 
Chemotherapy versus erlotinib 
as second-line treatment in 
patients with advanced non-
small cell lung cancer and wild-
type epidermal growth factor 
receptor: an individual patient 
data (IPD) analysis. ESMO Open 
2018;3:e000327. doi:10.1136/
esmoopen-2018-000327
Received 12 January 2018
Revised 15 March 2018
Accepted 19 March 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Michela Cinquini;  michela. 
cinquini@ marionegri. it
© Author (s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. Published 
by BMJ on behalf of the 
European Society for Medical 
Oncology.
AbstrAct
The efficacy of second-line treatment in patients with 
epidermal growth factor receptor (EGFR) wild-type tumours 
is still debatable. We assessed the efficacy of a standard 
second-line chemotherapy compared with erlotinib in an 
individual patient data approach for meta-analysis. The 
primary endpoint was overall survival (OS), and secondary 
endpoint was progression-free survival (PFS). Both were 
compared by log-rank test. The ‘restricted mean survival 
time’ (RMST) was estimated in each study and the 
difference in mean survival time up to the last available 
time point was calculated. The Cox proportional hazards 
model was used on survival analyses to provide HRs, 
to adjust for confounding variables and to test possible 
interaction with selected factors. Three randomised trials 
comparing chemotherapy versus erlotinib were analysed, 
including 587 randomised patients. Overall, 74% of 
patients included in the original trials were considered. 464 
deaths and 570 progressions or deaths were observed. 
Compared with erlotinib, chemotherapy was associated to 
a decreased risk of progression (29%; HR: 0.71, 95% CI: 
0.60 to 0.84, p< 0.0001;) but with no statistical significant 
reduction in OS (HR: 0.89, 95% CI: 0.74 to 1.06; p<0.20). 
No heterogeneity was found in both analyses. Patients 
treated with chemotherapy gained an absolute 1.5 and 1.6 
months, respectively, in PFS and lifetime (RMST 95% CI: 
PFS 0.49 to 2.44; OS 95% CI: −1.04 to 4.25). These results 
showed that patients without a constitutively activated 
EGFR had better PFS with chemotherapy rather than with 
erlotinib while no statistical difference was observed in OS.
IntroduCtIon
Lung cancer is the leading cause of cancer 
death worldwide, and non-small cell lung 
cancer (NSCLC) accounts for approximately 
80% of cases. Most patients presented with 
advanced disease at the time of diagnosis, 
with an estimated median overall survival 
(OS) inferior to 10 months.1
In 2004, two classes of somatic activating 
mutation s were described, for the first 
time, in the tyrosine kinase (TK) domain of 
the epidermal growth factor receptor gene 
(EGFR) in patients with advanced NSCLC. In 
vitro experiments showed that these molec-
ular alterations determine the ligand inde-
pendent activation of the EGFR pathway, thus 
making tumour cells sensitive to the small 
molecule epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI), gefi-
tinib.2 This finding has opened a new era in 
the treatment of lung cancer.
Thanks to the technological advances, 
several molecular alterations, amenable of 
targeted inhibition, have been discovered 
in NSCLC, particularly in the subgroup of 
patients with adenocarcinoma,3 substantially 
improving the first-line treatment options 
for metastatic lung cancer. Currently, 
patients who carry EGFR activating muta-
tions or translocations in the anaplastic 
lymphoma kinase gene are treated upfront 
with their specific inhibitor, while chemo-
therapy remains the standard therapeutic 
choice for wild-type (WT) patients. While 
this distinction appears clear in first-line 
setting, for patients with EGFR WT or for 
individuals with undetermined mutation 
status, data from literature did not show 
a definite superiority of standard second-
line chemotherapy regimens (docetaxel 
or pemetrexed) over TKIs. In the past 
years, several studies have been conducted, 
comparing EGFR-TKIs (erlotinib or gefi-
tinib) to second-line chemotherapy in 
 o
n
 27 D
ecem
ber 2018 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2018-000327 on 1 Novem
ber 2018. Downloaded from
 
Open access
2 Garassino MC, et al. ESMO Open 2018;3:e000327. doi:10.1136/esmoopen-2018-000327
patients with NSCLC, independently of the EGFR geno-
type or focusing on WT patients only.4
Currently, for the treatment of patients with advanced 
NSCLC in the second-line setting regardless their muta-
tional status, US Food and Drug Administration (FDA) 
approved, other than docetaxel and pemetrexed, the 
EGFR-TKI erlotinib, even though its role seems not to be 
appropriate for WT patients. This issue has been shown 
by several systematic reviews with meta-analysis that tried 
to pool together the aggregated data derived from these 
studies, just concluding that WT patients are not suitable 
for TKIs option.4–6
This came to an end when, in 2016, the FDA modi-
fied the indication for erlotinib (or treatment of NSCLC 
limiting its use to patients whose tumours have specific 
EGFR mutations).
Nevertheless, it is of great importance to obtain all 
the information needed even from those trial reporting 
results from subgroups. Possible imbalances between 
arms might be managed by appropriate analyses.
We tried in contacting all authors of relevant studies 
with the aim at performing an individual patient data 
(IPD) meta-analysis that could improve the quality of 
data and the type of analyses and produce more reliable 
results.
We also identified factors that might affect the effect 
of erlotinib on OS and provide an unique opportunity 
to shed light on this important topic. The study allows 
for a deeper analysis of the pooled data of these three 
studies, adding the information that, based on the avail-
able markers and clinical factors, there is no subgroup of 
patients with WT NSCLC who can take advantages from a 
therapy based on erlotinib.
MaterIals and Methods
Identification of eligible trials
On January 2015, we performed a comprehensive search 
to identify all phase III randomised trials comparing 
chemotherapy over erlotinib in second line.
We searched PubMed, Embase and the Cochrane 
Library for papers published until January 2015 with the 
following keywords: “erlotinib”, “TKI”, “lung neoplasms”, 
“NSCLC” and “Randomized Controlled Trial”.
We also searched the proceedings of the most important 
international meetings (American Society of Clinical 
Oncology, European Society of Medical Oncology, Euro-
pean Cancer Conference and World Conference on Lung 
Cancer) from 2005 onwards until January 2015.
Studies had to be closed to patient accrual and have at 
least one survival outcome (OS, progression-free survival 
(PFS)) to be included.
Studies were excluded if the percentage of genotyped 
patients was less than 50% to better generalise the results.
data collection and database quality
For all patients enrolled, we requested individual data 
to the authors of each identified trial. Before we did the 
pooled analyses, we checked the data from each individual 
study and verified them for coherence with the original 
publications, and we discussed any discrepancies with 
the authors. Database quality was good for all the eligible 
studies. Data for survival analyses, and possible prognostic 
or predictive factors for all randomised patients were 
required and provided following an ‘ad hoc’ case report 
form.
Adverse events were not analysed because this issue is 
not related to subgroups only but it is a general aspect 
that affects the entire population.
statistical analysis
The analyses were performed on all randomised patients 
meeting the inclusion criteria, according to the intention-
to-treat principle. OS was defined as the time from rando-
misation until death. Patients still alive were censored at 
the date of last follow-up. PFS was defined as the time 
from randomisation until progression or death whichever 
occurred first. Patients alive without disease progression 
were censored at the date of last follow-up.
As primary analysis, OS and PFS curves were estimated 
by the Kaplan-Meier technique, and the null hypothesis 
of no difference between the two arms was assessed using 
the log-rank test stratified by trial. The Cox proportional 
hazards model was used on both survival analyses to 
provide an estimate of the HR, to adjust for confounding 
variables and to test possible interaction with selected 
factors.
As secondary analysis, the ‘restricted mean survival 
time’ (RMST), a model-free and censoring-indepen-
dent parameter to quantify the treatment difference, 
was estimated in each singular study, and the difference 
between arms in mean survival time up to the last avail-
able time point were calculated. When the proportional 
hazards assumption is not valid, the standard maximum 
partial likelihood estimator of the HR approximates a 
parameter which is difficult, if not impossible, to interpret 
as the treatment contrast. Therefore, it is highly desirable 
to consider an estimable, model-free and censoring-in-
dependent parameter to quantify the treatment differ-
ence.7 8
This approach returns an easily interpretable, clinically 
meaningful summary of the survival function in the pres-
ence of censoring. The RMST is the average of all poten-
tial event times measured up to a time point t*, which can 
be estimated consistently by the area under the Kaplan-
Meier curve over [0;t*].
For the pooled analysis, 1 year for PFS and 2 years for 
OS were used as last available time point mean and SD 
of RMST were the effect measure used for meta-analysis.
For all pooled analyses, the inverse variance method 
was used for weighting the results of each trial. A random 
effect model was considered because an a priori heteroge-
neity among studies was thought and a χ2 heterogeneity 
tests was used to test it. We also calculated the I2 statistic 
to measure inconsistency among trials.
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If there were sufficient data available, we investigated 
whether any observed treatment effect was consistent or 
not across well-defined patient subgroups. These analyses 
were carried out on all trials and were stratified by trial. 
Then subgroup analyses were done within treatment cate-
gories identified as race, sex, histology and smoking status 
and K-ras mutation status.
χ2 tests for interaction or trend was used to test whether 
there was any evidence that types of patients benefit from 
chemotherapy.
All statistical analyses were carried out using SAS V.9.4 
with a significant level of 0.05; all meta-analyses were 
performed with RevMan 5.3.9
results
Overall 7 out of 133 studies were found to meet eligible 
criteria for randomised comparison of chemotherapy 
versus erlotinib in second-line treatments for NSCLC10–16 
for which we contacted corresponding authors. The 
studies of Lee13 and Li16 were excluded because of phase 
II studies. No data were available for the study HORG14 
and TITAN15 because authors never answered to our 
request.
The analysis of the three remaining studies included all 
587 patients randomised into the trials (number of erlo-
tinib/chemotherapy: all 303/284; TAILOR10109/110; 
DELTA12 109/90; PROSE11 85/84); overall, 74% of 
patients included in the trials were considered (TAILOR 
219/222: 99%; DELTA 199/301: 66%; PROSE 169/302: 
62%).
Table 1 describes the characteristics of evaluated 
patients per study group.
Overall, a good balancing of baseline characteristics 
was achieved between treatments. Analysis across studies 
showed that DELTA study had a proportion of male higher 
than the TAILOR and PROSE, and a lower proportion of 
smokers.
TAILOR had as primary objective whether patients with 
EGFR WT could benefit from treatment with docetaxel 
or erlotinib. DELTA, in which an Asian population was 
enrolled, wanted to show the superiority of erlotinib over 
docetaxel in second-third line, in patients not selected for 
EGFR mutation status. PROSE, had a different concep-
tion yet, as it wanted to demonstrate that a proteomic 
signature could select patients either for chemotherapy or 
erlotinib. Moreover, in both DELTA and PROSE studies, 
a subgroup analysis, testing the interaction between 
Table 1 Baseline characteristics of included studies
TAILOR PROSE DELTA
Chemo: 110 Erl: 109 Chemo: 84 Erl: 85 Chemo: 90 Erl: 109
n % n % n % n % n % n %
Age median (minimum– 
maximum)
65 (33–81) 64 (39–78) 64 (42–77) 67 (47–81) 67 (36–85) 66 (37–82)
Gender 
  Male 73 66.4 77 70.6 60 71.4 59 69.4 68 75.6 85 78.0
  Female 37 33.6 32 29.4 24 28.6 26 30.6 22 24.4 24 22.0
Smoke habits 
  Never smoker 30 27.3 19 17.4 7 8.3 9 10.6 14 15.6 22 20.2
  Ex smoker 52 47.3 55 50.5 51 60.7 54 63.5 68 75.6 82 75.2
  Current smoker 28 25.5 35 32.1 26 31.0 22 25.9 8 8.9 5 4.6
Histology 
  Squamous 21 19.1 25 22.9 12 14.3 21 24.7 19 21.1 22 20.2
  Adenocarcinoma 74 67.3 69 63.3 58 69.0 50 58.8 58 64.4 72 66.1
  Bronchioloalveolar 2 1.8 3 2.8 1 1.2 2 2.4 NA NA NA NA
  Large cell 2 1.8 NA NA 4 4.8 6 7.1 4 4.4 7 6.4
  Mixed 1 0.9 1 0.9 NA NA NA NA NA NA NA NA
  Other 6 5.5 8 7.3 7 8.3 5 5.9 9 10.0 8 7.3
  Not known 4 3.6 3 2.8 2 2.4 1 1.2 NA NA NA NA
Performance status
  0 53 48.2 52 47.7 43 51.2 46 54.1 38 42.2 52 47.7
  1 50 45.4 48 44.0 36 42.9 34 40.0 49 54.5 52 47.7
  2 7 6.4 9 8.3 5 5.9 5 5.9 3 3.3 5 4.6
Chemo, chemotherapy; Erl, erlotinib; NA, not applicable.
 o
n
 27 D
ecem
ber 2018 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2018-000327 on 1 Novem
ber 2018. Downloaded from
 
Open access
4 Garassino MC, et al. ESMO Open 2018;3:e000327. doi:10.1136/esmoopen-2018-000327
EGFR mutations and treatment, was preplanned, and the 
majority of the enrolled patients was EGFR WT.
In TAILOR and DELTA, only patients with histological 
diagnosis were enrolled, while PROSE allowed to enter 
also patients with cytological diagnosis. Furthermore, in 
both TAILOR and PROSE, the CT scan evaluation was 
performed every 8 weeks, while in DELTA, the radiolog-
ical assessment was performed every month for the first 
4 months, and then every 2 months. Moreover, while in 
TAILOR and PROSE, docetaxel was administered at the 
dose of 75 mg/m2 every 21 days or at 35 mg/m2 on days 1, 
8, 15, every 28 days, patients enrolled in DELTA received 
60 mg/m2 every 21 days. Finally, while tumour samples 
from patients enrolled in TAILOR and DELTA were anal-
ysed according to the Sanger method, those from patients 
recruited in DELTA were genotyped by a highly sensitive 
PCR method, the PCR-invader method, peptide nucleic 
acid-locked nucleic acid PCR clamp method.
PFs and overall survival analysis
Figure 1 and figure 2 report the survival curves for OS 
and PFS, respectively. Four hundred and sixty-four 
deaths and 570 progressions or deaths were observed. 
Compared with erlotinib, chemotherapy was associated to 
a decreased risk of progression (29%) but with no reduc-
tion in OS (HR-PFS: 0.71, 95% CI: 0.60 to 0.84, p<0.0001; 
HR-OS: 0.89, 95% CI: 0.74 to 1.06; p<0.2, figure 3A,C). 
No heterogeneity was found in both analyses.
Patients treated with chemotherapy gained an abso-
lute 1.5 and 1.6 months, respectively, in progression-free 
survival and lifetime (RMST 95% CI: PFS 0.49 to 2.44; OS 
95% CI: −1.04 to 4.25).
In this case, we found a moderate heterogeneity (36% 
and 47%, respectively, for PFS and OS) likely because this 
type of analysis is affected by extreme values (figure 3B,D).
OS results were confirmed after adjustment by age, 
gender, smoking habit, performance status, histotype 
and K-RAS (HR-OS: 0.87, 95% CI: 0.72 to 1.04; p<0.137) 
(table 2).
Among the factors evaluated for possible prognostic 
effect on survival, only gender (female) and performance 
status (0) were found to be associated to a better prog-
nosis (table 2). No factors resulted associated to a differ-
ential effect of therapy (figure 4).
dIsCussIon
In the last years, the question about treating EGFR WT 
NSCLC patients with erlotinib has been the focus of 
much debate.
When TAILOR, DELTA and PROSE were designed, the 
predictive role of EGFR activating mutations was not yet 
clear, and the therapeutic options in second-line setting 
were weak, based only on single agent chemotherapy or 
erlotinib, but with any criteria to select population.
Figure 1 Overall survival. Kaplan-Meier curve. mos, months.
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With the aim to compare the efficacy of standard 
second-line chemotherapy and erlotinib in EGFR WT 
NSCLC patients, we performed this IPD analysis. The 
three studies selected, although from different rational 
and objectives, shared the same study design. Despite 
these differences, results were similar, being the PFS in 
favour of chemotherapy in EGFR WT patients. Unfor-
tunately, only results from TAILOR showed a longer OS 
in the chemotherapy arm. It is important to emphasise 
that TAILOR did not allow the cross-over treatment in 
further lines and that only taxane naive patients were 
included, while PROSE and DELTA allowed previous 
taxane therapy. Furthermore, pemetrexed was an option 
for the second-line chemotherapy only in the PROSE 
study. These differences are potentially responsible of 
differing results of these three trials, even though these 
aspects did not reflect in heterogeneity when data were 
analysed using the common method.
Heterogeneity appears when results are presented as 
mean difference. This may be due to the fact that the 
effect measure suffers from extreme values.
The strength of this meta-analysis is that the results 
give us a more accurate estimate of the benefit of chemo-
therapy compared with erlotinib.
Having all the row data allowed for a very sensitive anal-
ysis of factors potentially associated to survival. Based on 
this analysis, we can conclude that there is no evidence 
of predictive role of investigated factors, and only 
performance status and gender results to be associated 
with prognosis. This was already the primary endpoint 
of PROSE trial with the hypothesis of demonstrating 
the existence of a significant interaction between the 
proteomic test and the treatment. Unfortunately, this was 
the only trial with such a design.
The weakness lies in the fact that not all trials with the 
required characteristics were included in this analysis 
because on one hand we did not receive answer from all 
the contacted authors, but on the other hand we arbi-
trary chose a minimum percentage of genotyped patients 
(>50%) to be included in the analysis.
A generalisation of these results is not easy to achieve 
even because patient characteristics among studies 
differed remarkably, that is, in the PROSE study there 
were considerable number of squamous and KRAS 
mutated patients; DELTA has a totally Asian population, 
while the others Caucasian.
Is this meta-analysis enough to say that no longer erlo-
tinib should not be given in patients with EGFR WT? 
Since all three studies show that even a small percentage 
of patients despite the absence of EGFR mutations will 
benefit from erlotinib, research should focus on this 
question. One hypothesis is to evaluate if they are EGFR 
mutated patients and the Sanger’s sequencing is not 
enough sensitive to recognise them or if they are patients 
with other alterations that somehow also activate the EGFR 
pathway. For instance, EGFR-kinase domain duplication 
Figure 2 Progression-free survival. Kaplan-Meier curve. mos, months.
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(KDD) recently was identified and documented that a 
patient with metastatic lung adenocarcinoma harbouring 
the EGFR-KDD derived significant antitumour response 
from treatment with the EGFR inhibitor afatinib. 
However, we are confident that in patients with good 
Eastern Cooperative Oncology Group performance status 
and able to tolerate chemotherapy in second line, based 
on these findings, a chemotherapeutic treatment should 
be preferred before using EGFR-TKI. Another key ques-
tion is whether all this discussion will end with the new 
Figure 3 Forest plot of combined HRs for progression-free survival (A); forest plot of combined difference in mean (RMSD) 
for progression-free survival (B); forest plot of combined HRs for overall survival (C); forest plot of combined difference in mean 
(RMSD) for overall survival (D). IV, inverse of variance; RMSD, root-mean-square deviation.
Table 2 Multivariable analysis of prognostic factors for overall survival
Factor Ref. Level HR 95% CI P values
Treatment Chemotherapy Erlotinib 0.87 0.72 to 1.04 0.137
Age (years) Continous 1.00 0.99 to 1.01 0.690
Gender Female Male 0.73 0.58 to 0.93 0.011
Smoke habits Former Current 1.08 0.85 to 1.36 0.643
Never 0.95 0.68 to 1.34
Histology Non-squamous Squamous 0.87 0.69 to 1.11 0.258
Performance status >0 0 1.74 1.49 to 2.03 <0.001
K-ras* Mutated Non-mutated 1.28 0.99 to 1.65 0.066
Analysis is stratified by study. 
*Evaluated only in TAILOR and PROSE trials.
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arrival of immunotherapy and combination of docetaxel 
with nintedanib or ramucirumab? The answer is no. In 
fact, it is already clear that the innovative therapies are 
not applicable for all patients. Therefore, it is possible 
that the treatment of the lung cancer in the future will 
have a therapeutic algorithm much more complex than 
now. Patients will be tested for a much greater number 
of alterations including all the new discovered activating 
mutations. In principle, it is possible that for most acti-
vating mutations there will be their specific correspon-
dent inhibitor. A fraction of patients who do not have an 
activating mutation will be candidate for this promising 
new class of drugs targeting the immune checkpoints and 
the remaining ones still for chemotherapy alone or in 
combination with new agents.
The future is very promising with many treatment 
options unimaginable when TAILOR, DELTA and PROSE 
had been drawn, but the old chemotherapy remains a 
part of therapeutic choices alone or in combination. We 
currently have much more therapeutic opportunities, and 
the appropriate question is what are the considerations 
that must be included in decision process to propose 
the best therapeutic option for the single patient. The 
therapeutic choice will not only be defined by promising 
survival outcomes of the novel therapeutic approaches, 
but it will be determined by patients’ comorbidities, 
biomolecular and radiological tumour characteristics and 
by overall patients’ preference.
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